Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fennec Pharmaceuticals Inc. (FENC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed under its Exchange Act reporting obligations. Fennec is a specialty pharmaceutical company focused on PEDMARK®, a sodium thiosulfate injection indicated to reduce the risk of cisplatin-induced ototoxicity in certain pediatric cancer patients.
Recent Form 8-K filings describe material definitive agreements and financing activities, such as an underwriting agreement for an underwritten registered public offering of common shares and subscription agreements for a non-brokered offering of common shares in Canada. These filings outline key terms of the offerings, the number of shares issued, the public offering price and the use of proceeds.
Other 8-K reports detail a Waiver and Redemption Agreement with Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, under which Fennec agreed to repurchase and redeem its remaining senior secured floating rate convertible notes. The company reports that, after completing this transaction, all payment obligations under the notes were satisfied in full, and related news releases are incorporated by reference in the filings.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools can help readers quickly identify the purpose of each filing, such as equity offerings, debt redemptions or other corporate events, and understand how they relate to Fennec’s ongoing commercialization of PEDMARK® and its capital structure. Users can also track exhibits referenced in the 8-Ks, including underwriting agreements, subscription agreements, legal opinions and press releases.
Cioffi Christiana Marie reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported compensation-related equity awards. She received incentive stock options for 120,000 common shares at $5.77 per share, expiring on March 31, 2036, under the 2020 Equity Incentive Plan. Performance share units and previously awarded restricted shares also vested, increasing her directly held common shares to 23,865 as of March 28, 2026.
FENNEC PHARMACEUTICALS INC. reported that Chief Executive Officer Jeffrey S. Hackman received an incentive stock option grant to purchase 200,000 common shares at $5.77 per share, expiring on March 31, 2036, under the company’s 2020 Equity Incentive Plan.
On March 31, 2026, one-third of these options become exercisable, with additional portions vesting monthly so that all 200,000 options are vested by March 31, 2029. Hackman also acquired additional common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025.
FENNEC PHARMACEUTICALS director Rosty Raykov exercised stock options and sold shares in a largely pre-planned, tax-related transaction. On April 1, 2026, he exercised 15,598 stock options at $2.45 per share, acquiring the same number of common shares under a Rule 10b5-1 trading plan adopted on September 19, 2025. On the same date, he sold 10,946 common shares at $6.31 per share to satisfy tax obligations related to the option exercise, also under that plan. A day earlier, on March 31, 2026, he received 5,208 common shares as a grant released from prior restricted awards. After these trades, he directly owned 113,856 common shares, indicating he retained most of the exercised shares.
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported equity compensation activity. On March 31, 2026, he received incentive stock options for 120,000 common shares at $5.77 per share, expiring March 31, 2036, under the 2020 Equity Incentive Plan.
One-third of these options vest on March 31, 2027, with additional vesting monthly until fully vested by March 31, 2029. The filing also shows settlement of performance share units and release of restricted shares, bringing direct holdings to 20,679 common shares. All transactions reflect awards and vesting rather than open‑market trading.
Andrade Robert reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. reported insider equity awards for Chief Financial Officer Robert Andrade. On March 31, 2026, he received incentive stock options to purchase 120,000 common shares at $5.77 per share under the 2020 Equity Incentive Plan, vesting monthly from March 31, 2027 until March 31, 2029.
On the same date, 14,724 common shares were issued from settlement of PSUs that vested, and 2,213 common shares were released from restriction from prior awards. On March 28, 2026, 12,270 additional common shares were released from restriction from a 2025 award. Following these transactions, he directly holds 273,593 common shares and 921,045 stock options.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L Evans received an incentive stock option grant covering 120,000 common shares at an exercise price of $5.77 per share. The options were granted under the 2020 Equity Incentive Plan and vest over time, with one-third exercisable as of March 31, 2027 and the remainder vesting monthly so that all are vested by March 31, 2029.
On the same date, Evans also acquired common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025. Following these equity awards and releases, Evans directly holds 20,679 common shares and 270,000 stock options, reflecting routine compensation-related transactions rather than open-market buying or selling.
The filing notifies sales of 10,946 shares of Common Stock via a stock option exercise reported as an issuer transaction on 04/01/2026. It also lists three reported open-market dispositions in the prior three months: 10,079 shares for $84,354.17, 10,349 shares for $80,339.29, and 10,312 shares for $78,471.23.
Fennec Pharmaceuticals is a commercial-stage specialty pharma company focused on preventing cisplatin-induced hearing loss with its drug PEDMARK in the U.S. and PEDMARQSI in Europe and other regions. The product is FDA- and European Commission-approved for pediatric patients with localized, non-metastatic solid tumors and showed about a 50% relative reduction in hearing loss versus cisplatin alone in clinical studies.
In March 2024, Fennec signed an exclusive licensing deal with Norgine, receiving about $43 million upfront, with up to about $230 million in potential milestones and double-digit tiered royalties on PEDMARQSI net sales. Norgine launched PEDMARQSI in Germany and the U.K. in 2025, with further European launches expected. Fennec also added a 2025 distribution agreement with Inpharmus for Turkey and Gulf Cooperation Council countries and reported positive 2025 Japanese STS-J01 trial results, supporting a registration strategy and potential partnering there.
The company has U.S. Orphan Drug Exclusivity for PEDMARK until September 20, 2029 and European pediatric-use marketing exclusivity until May 26, 2033, alongside a broad patent estate expiring around 2039. In March 2026, Fennec settled litigation with Cipla over a proposed generic, with Cipla agreeing not to launch its sodium thiosulfate product before September 1, 2033, reinforcing PEDMARK’s commercial runway.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.
Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.